MLMichele Lombardo

Michele Lombardo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michele Lombardo has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Why Do Patients with Mitral Valve Prolapse Exercise Less? The Emerging Role of Thoracic Geometry

    by Andrea Sonaglioni, Michele Lombardo, Gian Luigi Nicolosi, Massimo Baravelli

    Background: Exercise intolerance is frequently reported in patients with mitral valve prolapse (MVP) despite preserved left ventricular (LV) systolic function and non-severe mitral regurgitation, but its mechanisms remain incompletely understood. We investigated whether antero-posterior (A-P) thoracic diameter is associated with reduced functional capacity in symptomatic MVP and characterized exercise-related changes in LV filling, stroke volume, and cardiac output. Methods: In this prospective single-center study, 101 consecutive symptomatic individuals undergoing exercise stress echocardiography (ESE) were enrolled, including 58 with MVP and 43 symptomatic non-MVP controls. Resting and exercise assessment included indexed LV volumes, stroke volume index (SVi), cardiac index (CI), LV filling indices, and pulmonary pressures. Reduced functional capacity was prespecified as peak workload < 100 W. Logistic regression and receiver-operating characteristic analyses were performed to identify its determinants and evaluate A-P thoracic diameter. Results: Patients with MVP had a smaller A-P thoracic diameter and lower exercise capacity than controls, with more frequent exertional symptoms and greater exercise-induced ST-segment depression despite negative ESE for inducible wall-motion abnormalities. At rest, MVP patients exhibited smaller LV dimensions and volumes, lower LV mass and left atrial size, and lower SVi and CI despite comparable LVEF and E/e′. During exercise, LV contractile reserve and pulmonary pressure responses were comparable, whereas peak LVEDVi, LVESVi, SVi, CI, and E/e′ were lower in MVP patients. Exercise-induced increases in LVEDVi, SVi, CI, and E/e′ were also attenuated. After multivariable adjustment, female sex (adjusted OR 4.14, 95% CI 1.22–14.05; p = 0.023) and A-P thoracic diameter (adjusted OR per 1 cm increase 0.30, 95% CI 0.16–0.58; p < 0.001) retained statistical significance, whereas the associations with anxiety disorder, MVP, and peak-exercise SBP were attenuated and no longer statistically significant. A-P thoracic diameter showed good discrimination (AUC 0.864), with an internally derived optimal cut-off ≤12.75 cm. Conclusions: Symptomatic MVP was characterized by reduced exercise capacity and a smaller, low-filling cardiac phenotype with limited stroke-volume and cardiac-output augmentation despite preserved LV contractile reserve. A smaller A-P thoracic diameter remained independently associated with reduced functional capacity after adjustment for MVP status and other covariates, supporting thoracic geometry as a component of a broader thoraco-cardiac functional phenotype. The identified threshold requires external validation.

    • 19 November 2026
    • Published by MDPI AG in Preprints.org
      • https://doi.org/10.20944/preprints202611.2076.v1
    Open Access

    Thoracic Geometry and Exercise Hemodynamics in Symptomatic Mitral Valve Prolapse: Development and Internal Validation of a Three-Variable Nomogram

    by Andrea Sonaglioni, Michele Lombardo, Gian Luigi Nicolosi, Massimo Baravelli, Cesare Cuspidi

    Background: Risk stratification remains challenging in symptomatic patients with mitral valve prolapse (MVP), preserved left ventricular (LV) systolic function, and non-severe mitral regurgitation (MR). Thoracic geometry and exercise-derived hemodynamics may provide complementary information on cardiovascular phenotype and clinical outcomes. This study investigated their associations with retrospectively documented cardiovascular events and developed an exploratory anatomical–functional nomogram. Methods: We included 140 symptomatic adults with MVP, LV ejection fraction ≥55%, and non-severe primary MR. Thoracic morphometry and exercise stress echocardiography were performed at the index assessment. Preceding non-fatal cardiovascular events requiring emergency or hospital-based care were retrospectively reconstructed. Cox regression was used to evaluate associations with historical event occurrence and develop a nomogram estimating 3- and 5-year event-free survival within the reconstructed observation period, with bootstrap internal validation. Results: Over a reconstructed observation period of 4.86 ± 4.62 years, 40 patients (28.6%) experienced at least one qualifying event: 4/58 (6.9%) with an antero-posterior (A-P) thoracic diameter < 13 cm versus 36/82 (43.9%) with a diameter ≥13 cm. Reduced thoracic depth was associated with smaller cardiac dimensions, less severe MR, and lower exercise-derived filling and pulmonary pressures, despite reduced exercise capacity and greater symptom burden. A-P diameter (hazard ratio [HR] per cm, 1.517; 95% confidence interval [CI], 1.090–2.111; p = 0.013), peak-exercise E/e’ (HR per unit, 1.177; 95% CI, 1.024–1.352; p = 0.022), and peak-exercise systolic pulmonary artery pressure (HR per mmHg, 1.073; 95% CI, 1.005–1.145; p = 0.034) were independently associated with the reconstructed composite endpoint. The three-variable nomogram achieved an apparent Harrell's C-index of 0.804 and an optimism-corrected C-index of 0.791, although calibration deviations were observed. Conclusions: Integrating thoracic geometry with exercise-derived LV filling and pulmonary hemodynamics may improve cardiovascular phenotypic characterization in symptomatic MVP without severe MR. However, because predictor measurements followed the reconstructed events, the nomogram does not establish prospective predictive validity. Independent prospective external validation is required before clinical implementation.

  • Open Access

    When Exercise ECG and Stress Echocardiography Disagree: Thoracic Geometry as a Potential Determinant of Exercise-Induced ST-Segment Abnormalities

    by Andrea Sonaglioni, Michele Lombardo, Gian Luigi Nicolosi, Massimo Baravelli, Marijana Tadic

    Background: Exercise-induced ST-segment depression may occur despite negative exercise stress echocardiography (ESE) and absence of obstructive coronary artery disease (CAD), creating diagnostic uncertainty in symptomatic patients. Whether thoracic geometry contributes to this discordant response remains poorly understood. We investigated factors associated with a positive exercise ECG despite negative ESE (ECG+/ESE−), with particular focus on antero-posterior (A-P) thoracic diameter. Methods: In this prospective, single-center study, 101 consecutive symptomatic patients undergoing evaluation for suspected obstructive CAD were enrolled. ESE and coronary computed tomography angiography (CCTA) were prospectively planned in all patients. A positive exercise ECG was defined by horizontal/downsloping ST-segment depression ≥ 1.0 mm or upsloping depression ≥ 1.5 mm. ESE was considered negative in the absence of new or worsening regional wall-motion abnormalities. Patients with ECG+/ESE− and ECG−/ESE− responses were compared, and factors associated with ECG positivity were assessed by logistic regression. The discriminatory performance of A-P thoracic diameter was explored using ROC analysis. Results: All patients had negative ESE and no obstructive CAD on CCTA, while 35 (34.7%) developed a positive exercise ECG. Compared with ECG−/ESE− patients, those with ECG+/ESE− exhibited a smaller A-P thoracic diameter and higher modified Haller index, together with distinctive cardiac geometry and more frequent MVP. After multivariable adjustment, MVP was independently associated with ECG positivity (adjusted OR 8.50, 95% CI 1.07–67.75; p = 0.043), whereas increasing A-P thoracic diameter showed a strong inverse association (adjusted OR per 1-cm increase 0.026, 95% CI 0.005–0.143; p < 0.001). Smaller A-P thoracic diameter was also associated with lower exercise capacity and chronotropic response, greater exercise-induced ST-segment depression, and lower peak-exercise E/e′. A-P thoracic diameter showed excellent discrimination (AUC 0.962, 95% CI 0.921–1.000; p < 0.001); a data-derived cut-off ≤ 10.95 cm yielded 97.1% sensitivity and 93.9% specificity. Conclusions: MVP and reduced A-P thoracic diameter were independently associated with exercise ECG positivity despite negative ESE and absence of obstructive CAD, supporting a distinct thoraco-cardiac phenotype associated with exercise-induced repolarization abnormalities despite preserved LV contractile reserve. A-P thoracic diameter may provide complementary phenotypic information when exercise ECG and ESE findings are discordant; however, its incremental clinical value and the proposed ≤ 10.95-cm threshold require external validation.

  • Open Access

    The Silent Face of Atrial Fibrillation: A Systematic Review of Associated Factors, Clinical Phenotype, and Outcomes

    by Andrea Sonaglioni, Giulio Francesco Gramaglia, Elena Mondazzi, Gian Luigi Nicolosi, Michele Lombardo, Massimo Baravelli

    Background: Asymptomatic atrial fibrillation (AF) is increasingly recognized through incidental diagnosis and continuous rhythm monitoring, yet its clinical phenotype and prognostic significance remain incompletely characterized. We systematically evaluated factors associated with asymptomatic AF and its clinical outcomes. Methods: This systematic review was conducted according to PRISMA 2020 recommendations. PubMed/MEDLINE, Scopus, and EMBASE were searched from inception through 1 September 2026. Studies reporting demographic, clinical, anthropometric, laboratory, electrocardiographic, imaging, or therapeutic correlates of asymptomatic AF and/or associated clinical outcomes were eligible. Given substantial clinical and methodological heterogeneity, evidence was synthesized using structured qualitative analyses and descriptive summaries of study-level data, without formal meta-analysis or inferential testing of aggregated between-group differences. Results: Twenty-three studies were included, comprising 47,456 patients with asymptomatic or subclinical AF and 126,894 participants in the corresponding comparator groups. Study-specific evidence identified male sex, lower ventricular rate, and long-standing persistent or permanent AF as relevant correlates of asymptomatic presentation. Greater left atrial remodeling, including larger atrial dimensions and impaired mechanical function, was also reported in selected studies of silent AF, whereas conventional left ventricular structure and systolic function showed relatively similar descriptive estimates across the available datasets. Selected studies identified metabolic biomarkers and thoracic morphology as additional potential correlates. Rhythm-control strategies and catheter ablation showed numerically lower utilization in descriptive summaries of asymptomatic AF, although the contributing populations were heterogeneous and not necessarily directly comparable. Prognostic findings were heterogeneous: mortality and thromboembolic outcomes were generally comparable between asymptomatic and symptomatic AF in several individual studies, whereas other investigations reported a greater burden of heart failure and heart failure-related events among symptomatic patients. Conclusions: Asymptomatic AF represents a heterogeneous clinical phenotype rather than a benign form of the arrhythmia. A lower ventricular response may attenuate symptom perception, while atrial remodeling and cardiovascular risk may progress despite the absence of symptoms. Symptom status should therefore not replace established cardiovascular risk assessment. Thoracic geometry may represent an additional determinant of symptom perception, although current evidence remains preliminary and requires prospective validation.

  • Open Access

    Why Do Patients With Mitral Valve Prolapse Exercise Less? The Emerging Role of Thoracic Geometry

    by Andrea Sonaglioni, Michele Lombardo, Gian Luigi Nicolosi, Massimo Baravelli

    Background: Exercise intolerance is frequently reported in patients with mitral valve prolapse (MVP) despite preserved left ventricular (LV) systolic function and non-severe mitral regurgitation, but its mechanisms remain incompletely understood. We investigated whether antero-posterior (A-P) thoracic diameter is associated with reduced functional capacity in symptomatic MVP and characterized exercise-related LV filling and forward-flow responses. Methods: In this prospective single-center study, 101 consecutive symptomatic individuals undergoing exercise stress echocardiography (ESE) were enrolled, including 58 with MVP and 43 symptomatic non-MVP controls. Resting and exercise assessment included indexed LV volumes, stroke volume index (SVi), cardiac index (CI), LV filling indices, and pulmonary pressures. Reduced functional capacity was prespecified as peak workload Results: Patients with MVP had a smaller A-P thoracic diameter and lower exercise capacity than controls, with more frequent exertional symptoms and greater exercise-induced ST-segment depression despite negative ESE for inducible wall-motion abnormalities. At rest, MVP patients exhibited smaller LV dimensions and volumes, lower LV mass and left atrial size, and lower SVi and CI despite comparable LVEF and E/e′. During exercise, LV contractile reserve and pulmonary pressure responses were comparable, whereas peak LVEDVi, LVESVi, SVi, CI, and E/e′ were lower in MVP patients. Exercise-induced increases in LVEDVi, SVi, CI, and E/e′ were also attenuated. After multivariable adjustment, female sex (adjusted OR 3.99, 95% CI 1.23–13.01; p=0.022) and A-P thoracic diameter (adjusted OR per 1-cm increase 0.32, 95% CI 0.17–0.58; pConclusions: Symptomatic MVP was characterized by reduced exercise capacity and a smaller, low-filling cardiac phenotype with limited forward-flow augmentation despite preserved LV contractile reserve. A smaller A-P thoracic diameter, rather than MVP status, remained independently associated with reduced functional capacity, supporting thoracic geometry as a component of a broader thoraco-cardiac functional phenotype. The identified threshold requires external validation.

  • Open Access

    Comorbidity Burden and Cumulative Anti-HER2 Exposure Associated with Cardiac Dysfunction in Breast Cancer: A Real-World Cardio-Oncology Cohort

    by Andrea Sonaglioni, Emanuela Fossile, Maria Adelaide Pessi, Maria Gemelli, Massimo Baravelli, Michele Lombardo, Gian Luigi Nicolosi, Barbara Bassani, Antonino Bruno, Paola Muti

    Background: Cancer-therapy-related cardiac dysfunction (CTRCD) remains an important complication of human epidermal growth factor receptor 2 (HER2)-targeted therapy in patients with breast cancer. Although conventional cardiovascular risk factors and serial cardiac imaging are routinely incorporated into cardio-oncology surveillance, the potential contribution of global comorbidity burden and cumulative anti-HER2 treatment exposure remains incompletely characterized. We investigated the occurrence, clinical course, and factors associated with CTRCD in a large real-world population of patients with breast cancer receiving HER2-targeted therapy. Methods: Adult patients with breast cancer exposed to HER2-targeted therapy and undergoing longitudinal cardio-oncology surveillance at a single tertiary center were retrospectively identified over a 10-year accrual period (January 2014–December 2024). Mean individual follow-up was approximately 2.0 years (range, 0.5–9.0 years). CTRCD was defined according to the harmonized International Cardio-Oncology Society (IC-OS) definitions incorporated into the 2022 ESC Guidelines on cardio-oncology, integrating left ventricular ejection fraction (LVEF), left ventricular global longitudinal strain (LV-GLS), and cardiac biomarkers when available. Baseline comorbidity burden was quantified using the Charlson Comorbidity Index (CCI), while cumulative anti-HER2 exposure was quantified according to the total number of treatment cycles. Factors associated with CTRCD were investigated using univariable and parsimonious multivariable logistic regression. Results: A total of 850 patients with breast cancer receiving anti-HER2 therapy were included. CTRCD occurred in 179 patients (21.1%) and was predominantly mild, whereas clinically overt heart failure occurred in 2.9%. LVEF and LV-GLS deteriorated at nadir and subsequently showed substantial recovery during follow-up. Conventional cardiovascular risk factors, previous anthracycline exposure, tumor grade, baseline LVEF, and baseline LV-GLS were not significantly associated with CTRCD. In multivariable analysis, increasing CCI (adjusted OR 1.35 per one-point increase, 95% CI 1.12–1.63; p = 0.002) and cumulative anti-HER2 exposure (adjusted OR 1.41 per five additional cycles, 95% CI 1.10–1.80; p = 0.006) remained associated with CTRCD after mutual adjustment. Progressively higher observed proportions of CTRCD were found across increasing CCI categories and cumulative anti-HER2 exposure levels. Conclusions: In this large real-world cohort assembled over a 10-year accrual period, CTRCD was relatively frequent but predominantly mild and reversible. Greater global comorbidity burden and cumulative anti-HER2 exposure were associated with a higher occurrence of CTRCD. However, the association with cumulative anti-HER2 exposure should be considered hypothesis-generating rather than causal because of potential time-dependent and reverse-causality bias. Prospective validation is required to determine their potential role in individualized cardiovascular surveillance.

  • Open Access

    Beyond the Mitral Valve: Thoracic Antero-Posterior Diameter Identifies Distinct Risk Phenotypes in Mitral Valve Prolapse

    by Andrea Sonaglioni, Michele Lombardo, Gian Luigi Nicolosi, Massimo Baravelli

    Background: Risk stratification in mitral valve prolapse (MVP) remains challenging, particularly in symptomatic patients without severe mitral regurgitation (MR) or left ventricular (LV) dysfunction. Thoracic geometry is frequently altered in MVP, but the clinical and prognostic significance of directly measured antero-posterior (A-P) thoracic diameter remains poorly defined. Methods: In this single-center retro-prospective observational study, 116 symptomatic adults with echocardiographically confirmed MVP, preserved LV ejection fraction (≥55%), and non-severe primary MR underwent clinical assessment, thoracic morphometry, echocardiography, speckle-tracking analysis, carotid ultrasonography, and exercise stress echocardiography (ESE). Patients were categorized using an a priori A-P diameter threshold of <13 or ≥13 cm (n = 58 each), after age- and sex-matching. Cardiovascular events were assessed separately during a retrospectively reconstructed pre-index period and prospective post-index follow-up. Cox regression, receiver operating characteristic (ROC), and Kaplan–Meier analyses were performed. Results: The <13-cm phenotype had smaller cardiac chambers, lower LV mass, less pronounced MR and mitral annular disjunction, but lower exercise capacity, more symptoms, and greater exercise-induced ST-segment abnormalities, without inducible regional wall-motion abnormalities on ESE. During the pre-index period (4.58 ± 4.37 years), 25 non-fatal cardiovascular events were identified: 4/58 (6.9%) versus 21/58 (36.2%) in the <13- and ≥13-cm groups, respectively. A-P diameter (adjusted HR per 1-cm increase, 1.773; 95% CI, 1.178–2.667; p = 0.006) and more-than-mild peak-exercise MR (adjusted HR, 3.486; 95% CI, 1.273–9.544; p = 0.015) were independently associated with pre-index events. During prospective follow-up (7.32 ± 1.14 months), 14 non-fatal cardiovascular events occurred, with no fatal cardiovascular events: 1/58 (1.7%) versus 13/58 (22.4%), respectively. A-P diameter (adjusted HR per 1-cm increase, 3.234; 95% CI, 1.821–5.745; p < 0.001) and more-than-mild peak-exercise MR (adjusted HR, 5.053; 95% CI, 1.104–23.125; p = 0.037) remained associated with subsequent events. A-P diameter showed high discrimination for post-index events (AUC, 0.952; 95% CI, 0.886–1.000; p < 0.001), and prospective event-free survival differed by the prespecified 13-cm threshold (log-rank p = 0.001). Conclusions: A-P thoracic diameter identifies distinct MVP phenotypes and was associated with both previous and subsequent cardiovascular events. These exploratory prospective findings support thoracic depth as a simple, radiation-free marker potentially complementary to conventional MVP risk assessment, requiring external validation.

  • Open Access

    When Exercise ECG and Stress Echocardiography Disagree: Thoracic Geometry as a Potential Determinant of Exercise-Induced ST-Segment Abnormalities

    by Andrea Sonaglioni, Michele Lombardo, Gian Luigi Nicolosi, Massimo Baravelli, Marijana Tadic

    Background: Exercise-induced ST-segment depression may occur despite negative exercise stress echocardiography (ESE) and absence of obstructive coronary artery disease (CAD), creating diagnostic uncertainty in symptomatic patients. Whether thoracic geometry contributes to this discordant response remains poorly understood. We investigated factors associated with a positive exercise ECG despite negative ESE (ECG+/ESE−), with particular focus on antero-posterior (A-P) thoracic diameter. Methods: In this prospective, single-center study, 101 consecutive symptomatic patients undergoing evaluation for suspected obstructive CAD were enrolled. ESE and coronary computed tomography angiography (CCTA) were prospectively planned in all patients. A positive exercise ECG was defined by horizontal/downsloping ST-segment depression ≥1.0 mm or upsloping depression ≥1.5 mm. ESE was considered negative in the absence of new or worsening regional wall-motion abnormalities. Patients with ECG+/ESE− and ECG−/ESE− responses were compared, and factors associated with ECG positivity were assessed by logistic regression. The discriminatory performance of A-P thoracic diameter was explored using ROC analysis. Results: All patients had negative ESE and no obstructive CAD on CCTA, while 35 (34.7%) developed a positive exercise ECG. Compared with ECG−/ESE− patients, those with ECG+/ESE− exhibited a smaller A-P thoracic diameter and higher modified Haller index, together with distinctive cardiac geometry and more frequent MVP. After multivariable adjustment, MVP was independently associated with ECG positivity (OR 38.06, 95% CI 1.86–778.55; p=0.018), whereas increasing A-P thoracic diameter showed a strong inverse association (OR per 1-cm increase 0.01, 95% CI 0.001–0.13; p< 0.001). Smaller A-P tho-racic diameter was also associated with lower exercise capacity and chronotropic response, greater exercise-induced ST-segment depression, and lower peak-exercise E/e′. A-P thoracic diameter showed excellent discrimination (AUC 0.962, 95% CI 0.921–1.000; p< 0.001); a data-derived cut-off ≤12.5 cm yielded 97.1% sensitivity and 93.9% specificity. Conclusions: MVP and reduced A-P thoracic diameter were independently associated with exercise ECG positivity despite negative ESE and absence of obstructive CAD, supporting a distinct thoraco-cardiac phenotype associated with exercise-induced repolarization abnormalities despite preserved LV contractile reserve. A-P thoracic diameter may provide complementary phenotypic information when exercise ECG and ESE findings are discordant; however, its incremental clinical value and the proposed ≤12.5-cm threshold require external validation.

  • Open Access

    Comorbidity Burden and Cumulative Anti-HER2 Exposure Associated with Cardiac Dysfunction in Breast Cancer: A 10-Year Cardio-Oncology Study

    by Andrea Sonaglioni, Emanuela Fossile, Maria Adelaide Pessi, Maria Gemelli, Massimo Baravelli, Michele Lombardo, Gian Luigi Nicolosi, Barbara Bassani, Antonino Bruno, Paola Muti

    Background: Cancer therapy-related cardiac dysfunction (CTRCD) remains an important complication of human epidermal growth factor receptor 2 (HER2)-targeted therapy in patients with breast cancer. Although conventional cardiovascular risk factors and serial cardiac imaging are routinely incorporated into cardio-oncology surveillance, the potential contribution of global comorbidity burden and cumulative anti-HER2 treatment exposure remains incompletely characterized. We investigated the occur-rence, clinical course, and factors associated with CTRCD in a large real-world population of patients with breast cancer receiving HER2-targeted therapy. Methods: Adult patients with breast cancer exposed to HER2-targeted therapy and undergoing longitudinal cardio-oncology surveillance at a single tertiary center between January 2014 and December 2024 were included. CTRCD was defined according to contemporary European cardio-oncology criteria integrating left ventricular ejection fraction (LVEF), left ventricular global longitudinal strain (LV-GLS), and cardiac biomarkers when available. Baseline comorbidity burden was quantified using the Charlson Comorbidity Index (CCI), while cumulative anti-HER2 exposure was quantified according to the total number of treatment cycles. Factors associated with CTRCD were investigated using univariable and parsimonious multivariable logistic regression. Results: A total of 850 patients with breast cancer receiving anti-HER2 therapy were included. CTRCD occurred in 179 patients (21.1%) and was predominantly mild, whereas clinically overt heart failure occurred in 2.9%. LVEF and LV-GLS deteriorated at nadir and subsequently showed substantial recovery during follow-up. Conventional cardiovascular risk factors, previous anthracycline exposure, tumor grade, baseline LVEF, and baseline LV-GLS were not significantly associated with CTRCD. In multivariable analysis, increasing CCI (adjusted OR 1.35 per one-point increase, 95% CI 1.12–1.63; p=0.002) and cumulative anti-HER2 exposure (adjusted OR 1.41 per five additional cycles, 95% CI 1.10–1.80; p=0.006) were independently associated with CTRCD. CTRCD probability progressively increased across higher CCI categories and with increasing cumulative anti-HER2 exposure. Conclusions: In this 10-year cardio-oncology cohort of patients with breast cancer, CTRCD was relatively frequent during HER2-targeted therapy but was predominantly mild, infrequently associated with overt heart failure, and frequently reversible. Global comorbidity burden and cumulative anti-HER2 exposure were independently associated with CTRCD, suggesting that cardiotoxic risk may reflect the interplay between baseline patient vulnerability and treatment-related bur-den. If prospectively validated, these readily available variables may provide additional information for longitudinal cardiovascular risk assessment and help individualize surveillance during prolonged HER2-targeted therapy.

  • Open Access

    Mitral Valve Prolapse and Anxiety Disorders: A Systematic Review of Evidence in Both Directions and Meta-Analysis

    by Andrea Sonaglioni, Giulio Francesco Gramaglia, Gian Luigi Nicolosi, Massimo Baravelli, Michele Lombardo

    Background: The association between mitral valve prolapse (MVP) and anxiety disorders has remained controversial for more than four decades because of heterogeneous psychiatric definitions, evolving echocardiographic diagnostic criteria, and conflicting findings across observational studies. We performed a systematic review to examine the available evidence in both directions of the MVP–anxiety relationship, together with a meta-analysis of anxiety-related outcomes among patients with MVP versus controls, and to evaluate the influence of different echocardiographic diagnostic criteria on this association. Methods: PubMed, Scopus, and EMBASE were systematically searched for observational studies evaluating either direction of the association between MVP and anxiety disorders. Studies assessing anxiety-related outcomes in patients with MVP or the prevalence of MVP among individuals with anxiety disorders were included in the systematic review. Quantitative synthesis was restricted to studies providing comparative data on dichotomous anxiety-related outcomes in MVP and control populations, using random-effects models to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs), whereas evidence concerning MVP prevalence among individuals with anxiety disorders was synthesized descriptively. Results: Seventeen studies published between 1979 and 2026 met the inclusion criteria, including 10 evaluating anxiety-related outcomes in patients with MVP and 7 assessing MVP prevalence among patients with anxiety disorders. Eight studies evaluating anxiety-related outcomes in MVP versus control populations were eligible for quantitative synthesis, whereas studies examining MVP among individuals with anxiety disorders contributed to the descriptive synthesis. Overall, patients with MVP showed a significantly higher prevalence of anxiety-related outcomes than controls (OR 1.78, 95% CI 1.15–2.75; p = 0.010), with no evidence of between-study heterogeneity (I2 = 0%). The association was significant in studies using 2D echocardiographic assessment but not in those using historical M-mode criteria, with no significant between-subgroup difference (p = 0.227). Meta-regression identified no significant influence of publication year, age, or sex on the pooled estimate. Sensitivity analyses showed that the pooled association was not disproportionately influenced by any single study. Conclusions: Patients with MVP exhibit a significantly increased prevalence of anxiety-related outcomes compared with controls, although no causal relationship or effect modification by echocardiographic method can be established. Conversely, evidence on MVP prevalence among individuals with anxiety disorders remains heterogeneous and currently supports only descriptive synthesis. Future prospective studies integrating standardized psychiatric assessment, contemporary echocardiographic criteria, and quantitative thoracic morphometry are warranted to clarify the underlying mechanisms and clinical implications.